Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Hony Capital

Investor type Private Equity Firm
Founders John Zhao

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 56
Average round size
info
The average size of a deal this fund participated in
$242M
Portfolio companies 42
Rounds per year 2.95
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 10
Key employees 17
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • E-Commerce
  • Food and Beverage
  • Health Care
  • Software
  • SaaS
Summary

Hony Capital appeared to be the VC, which was created in 2003. The fund was located in Asia if to be more exact in China. The main office of represented VC is situated in the Beijing.

The overall number of key employees were 17.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Hony Capital, startups are often financed by BlueRun Ventures, Tencent Holdings, T. Rowe Price. The meaningful sponsors for the fund in investment in the same round are Tencent Holdings, Temasek Holdings, SoftBank Investment Advisers. In the next rounds fund is usually obtained by SoftBank, Temasek Holdings, SoftBank Investment Advisers.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight WeWork, WeWork China, ofo. Among the most popular fund investment industries, there are Transportation, Real Estate. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The common things for fund are deals in the range of more than 100 millions dollars. The increased amount of exits for fund were in 2015. The fund is constantly included in 2-6 deals per year. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Hony Capital performs on 5 percentage points less the average number of lead investments. Considering the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Hony Capital is more than 1 billion dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Hony Capital:
Typical Co-investors
Hony Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Hony Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alten Boulogne-Billancourt, France, Ile-de-France
Altos Capital Partners -
Bauwens Digital Cologne, Germany, Nordrhein-Westfalen
Codeworks DEV -
Fair4All Finance England, London, United Kingdom
Japan Property Management Center Japan, Tokyo
Lord Baltimore Investment Partners -
Movens Capital Mazowieckie, Poland, Warsaw
MTS Health Partners New York, New York, United States
Primary Capital England, London, United Kingdom
QBN Capital China, Guangdong, Wanchai
Rosario Capital LTD Israel, Tel Aviv, Tel Aviv District
Shenzhen Huashang Dingxin Equity Investment Fund Management China, Guangdong, Shenzhen
ShiYuKe TouZi Beijing, Beijing, China
South Park Ventures California, San Francisco, United States
Tengram Capital Partners Connecticut, United States, Westport
UNITED VENTURE CAPITAL Japan, Tokyo
VMG Partners California, San Francisco, United States
Weiss, Peck & Greer Venture Partners -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Starna Therapeutics

Biotechnology
Therapeutics
$23M16 May 2022 Suzhou, Jiangsu, China

Fuji Inc

21 Dec 2021 -

RootPath Genomics

Biotechnology
$50M07 Sep 2021 Cambridge, Massachusetts, United States

Seesaw Coffee

Coffee
Consumer
Food and Beverage
$15M16 Aug 2021 Shanghai, China

Seesaw Coffee

Coffee
Consumer
Food and Beverage
$15M22 Jul 2021 Shanghai, China

G+ ERP

$27M05 Jul 2021 -

StarPony

E-Commerce
Manufacturing
Toys
25 Jun 2021 Guangzhou, Guangdong, China

Chongxing Chongwu

$61M25 May 2021 Shanghai, Shanghai, China

Dingdong Maicai

E-Commerce
Food and Beverage
Sales
$700M06 Apr 2021 Shanghai, China
News
EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

– EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120m Series C financing round.
– The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital.
– Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hony Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: